HROW

Harrow (HROW)

Harrow Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:HROW

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/15	20:00	Business Wire	Harrow to Present at Two Investor Conferences in May	NASDAQ:HROW	Harrow Inc
2024/05/14	05:01	Business Wire	Harrow Announces First Quarter 2024 Financial Results	NASDAQ:HROW	Harrow Inc
2024/05/13	20:00	Business Wire	Harrow Names Greg DiPasquale as Senior Vice President, Head of Commercial	NASDAQ:HROW	Harrow Inc
2024/04/25	20:00	Business Wire	Harrow Will Release First Quarter 2024 Financial Results After Market Close on May 13, 2024	NASDAQ:HROW	Harrow Inc
2024/04/02	21:16	Business Wire	Melt Pharmaceuticals Closes $24 Million Series B Preferred Stock Financing	NASDAQ:HROW	Harrow Inc
2024/03/20	20:15	IH Market News	JPMorgan boosts dividends, Chipotle unveils 50:1 stock split, and Latest News	NASDAQ:HROW	Harrow Inc
2024/03/20	06:45	Business Wire	Harrow Announces Fourth Quarter and Year-End 2023 Financial Results	NASDAQ:HROW	Harrow Inc
2024/03/19	20:27	IH Market News	US Index Futures Decline Ahead of Federal Reserve Meeting, Oil Prices Retreat	NASDAQ:HROW	Harrow Inc
2024/03/06	20:06	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:HROW	Harrow Inc
2024/03/05	21:00	Business Wire	Harrow Will Release Fourth Quarter and Year-End 2023 Financial Results After Market Close on March 19, 2024	NASDAQ:HROW	Harrow Inc
2024/02/22	09:30	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:HROW	Harrow Inc
2024/02/22	09:29	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:HROW	Harrow Inc
2024/02/16	06:15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:HROW	Harrow Inc
2024/02/16	06:01	Business Wire	Harrow Licenses Canadian Rights to Apotex for Five Branded Ophthalmic Pharmaceutical Products	NASDAQ:HROW	Harrow Inc
2024/02/10	06:05	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:HROW	Harrow Inc
2024/02/08	21:30	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:HROW	Harrow Inc
2024/01/30	06:30	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:HROW	Harrow Inc
2024/01/30	05:26	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:HROW	Harrow Inc
2024/01/29	21:00	Business Wire	Harrow Announces New Appointments to its Board of Directors	NASDAQ:HROW	Harrow Inc
2024/01/11	21:00	Business Wire	Harrow Announces Availability of VEVYE® (Cyclosporine Ophthalmic Solution) 0.1%, the First and Only Cyclosporine-Based Product Indicated for Treating Both Signs and Symptoms of Dry Eye Disease	NASDAQ:HROW	Harrow Inc
2024/01/10	00:16	Edgar (US Regulatory)	Form SC 13G - Statement of acquisition of beneficial ownership by individuals	NASDAQ:HROW	Harrow Inc
2024/01/03	22:00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:HROW	Harrow Inc
2024/01/03	21:15	Business Wire	Melt Pharmaceuticals Provides Corporate Update	NASDAQ:HROW	Harrow Inc
2024/01/03	21:00	Business Wire	Harrow Partners with Leading Healthcare Market Access Technology Platforms	NASDAQ:HROW	Harrow Inc
2023/11/29	21:00	Business Wire	Harrow Completes Transfer of the TRIESENCE® New Drug Application	NASDAQ:HROW	Harrow Inc
2023/11/20	21:00	Business Wire	Harrow to Present at Two Investor Conferences in November	NASDAQ:HROW	Harrow Inc
2023/11/17	06:05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:HROW	Harrow Inc
2023/11/15	09:02	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:HROW	Harrow Inc
2023/11/14	06:38	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:HROW	Harrow Inc
2023/11/14	06:34	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:HROW	Harrow Inc